| dc.identifier.citation | Jonathan P Rogers, Cameron Watson, James Badenoch, Benjamin Cross, Matthew Butler, Jia Song, Daish Hafeez, Hamilton Morrin, Emma, Rachel Rengasamy, Lucretia Thomas, Silviya Ralovska, Abigail Smakowski, Ritika Dilip Sundaram, Camille Kaitlyn Hunt, Mao Fong Lim, Daruj Aniwattanapong , Vanshika Singh, Zain Hussain, S tuti Chak raborty, Ella Burchill, Katrin Janse n, H einz Ho lling, De an Walton, Thomas A Pollak, Mark Ellul, Ivan Koychev, Tom Solomon, Benedict Daniel Michael, Timothy R Nicholson, Alasdair G Rooney. The neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. medRxiv preprint Feb 26 2021 | en |
| dc.description.abstract | There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2.
In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature and
estimate point prevalences for neurological and neuropsychiatric manifestations.
Methods
We searched MEDLINE, Embase, PsycInfo and CINAHL up to 18 July 2020 for randomised controlled trials,
cohort studies, case-control studies, cross-sectional studies and case series. Studies reporting prevalences of
neurological or neuropsychiatric symptoms were synthesised into meta-analyses to estimate pooled prevalence.
Results
13,292 records were screened by at least two authors to identify 215 included studies, of which there were 37
cohort studies, 15 case-control studies, 80 cross-sectional studies and 83 case series from 30 countries. 147 studies
were included in the meta-analysis. The symptoms with the highest prevalence were anosmia (43.1% [35.2—51.3],
n=15,975, 63 studies), weakness (40.0% [27.9—53.5], n=221, 3 studies), fatigue (37.8% [31.6—44.4], n=21,101, 67
studies), dysgeusia (37.2% [30.0—45.3], n=13,686, 52 studies), myalgia (25.1% [19.8—31.3], n=66.268, 76 studies),
depression (23.0 % [11.8—40.2], n=43,128, 10 studies), headache (20.7% [95% CI 16.1—26.1], n=64,613, 84
It is made available under a CC-BY 4.0 International license .
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
medRxiv preprint doi: https://doi.org/10.1101/2021.02.24.21252335; this version posted February 26, 2021. The copyright holder for this preprint 6 studies), anxiety (15.9% [5.6—37.7], n=42,566, 9 studies) and altered mental status (8.2% [4.4—14.8], n=49,326, 19 studies). Heterogeneity for most clinical manifestations was high.
Conclusions
Neurological and neuropsychiatric symptoms of COVID-19 in the pandemic’s early phase are varied and common.
The neurological and psychiatric academic communities should develop systems to facilitate high-quality
methodologies, including more rapid examination of the longitudinal course of neuropsychiatric complications of
newly emerging diseases and their relationship to neuroimaging and inflammatory biomarkers | en |